Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real‐world experience study
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.12945
Abstract: We followed for 2 years patients treated with direct‐acting agents (DAA) to assess long‐term durability of virologic response, improvement of liver function, reduction in liver stiffness (LS) and risk of hepatocellular carcinoma (HCC). The study… read more here.
Keywords: hepatocellular carcinoma; treatment; study; liver ... See more keywords